Past Events

November 16, 2021: The Pros & Cons of Controversial FDA Approvals

Art Krieg, CSO & Founder, Checkmate Pharmaceuticals

Christine McSherry, CEO, Casimir LLC

Erin Mistry, SVP Payer Strategy, Government Affairs & Trade, Cormedix

Martin Tolar, CEO, Alzheon

Moderated by Katie Brandt, Director, Caregiver Support Services & Public Relations, Mass General

Hospital Frontotemporal Disorders Unit


November 2, 2021: Cybersecurity Awareness: Protecting Yourself & Your Company

Ileana van der Linde, Executive Director, JP Morgan Cybersecurity Awareness

Global Program


October 18, 2021: The Rising Asymmetry in Deal Terms across our Ecosystem

John Delyani, CBO, Repertoire Immune Medicines

Lauren Foster, Director, MIT Life Sciences Technology Licensing Team

Michal Preminger, Head, Johnson & Johnson Innovation

Moderated by Brian Goldstein, Partner, Choate Hall & Stewart


September 13, 2021: Long-Term Planning in a Bull Market

Mike Gilman, CEO, Arrakis Therapeutics

Scott Hansen, EVP & Head of Life Sciences Venture Banking, Pacific Western Bank

Holly Whittemore, CFO, Nimbus Therapeutics

Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities


June 15, 2021: The SPAC Attack

Gregg Beloff, Managing Director, Danforth Advisors

Jason Meyenburg, CEO, Gemini Therapeutics

Geoff Meyerson, CEO & Co-founder, Locust Walk


May 11, 2021: The Future of RNA Therapies

Frank DeRosa, CTO, Translate Bio

Robert Meehan, Sr. Director, Clinical Development, Moderna

Jennifer Petter, Founder & CSO, Arrakis Therapeutics

Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities


April 7, 2021: Tax Policy Changes

Adam Frank, Head of Wealth Management, JP Morgan Securities

Fred Gordon, Sr. Director, National Tax, RSM

Moderated by Chris Cavallo, Partner, Tax Services, RSM


March 15, 2021: The Future of the JPM Healthcare Conference

Angus Grant, Chief Business Executive, BeiGene

Lis Leiderman, CFO & Head of Corporate Development, Decibel Therapeutics

Moderated by David Ke, Managing Director, Investment Banking, JP Morgan Securities


February 23, 2021: Leadership during COVID

Chris Garabedian, CEO, Xontogeny

Jodie Morrison, CEO, Cadent Therapeutics

Ramani Varanasi, President & CEO, X-Biotix Therapeutics

Moderated by Jennifer Reilly, President & COO, Safety Partners


October 13, 2020: Fundraising during a Pandemic (part 2)

Doug Carlson, CFO, Ikena Oncology

Nilesh Kumar, Partner, Novo Ventures

Scott Hansen, EVP, Head of Life Sciences, Pacific Western Bank

Brian Gallagher, Partner, Abingworth


September 24, 2020: Fundraising during a Pandemic

Stuart Chaffee, CBO, Praxis Medicines

Brian Gallagher, Partner, Abingworth

Keith Dionne, CEO, Casma Therapeutics

John Gustofson, Managing Director, AbbVie Ventures


February 3, 2020: Top Considerations when Engaging a Potential Strategic Partnership

Mary Lynne Hedley, President & COO, Tesaro

Briane Fenton, CBO, Translate Bio

Maude Tessier, CBO, Ikena Oncology

Moderated by Imran Nasrullah, Director, Strategic Partnering, BD & L, Boehringer-Ingelheim


December 2019: Building your C-Suite

Stuart Chaffee, CBO, Praxis Medicines

Michelle Doig, Partner, Omega Funds

Chris Robinson, Chief Talent Officer, Third Rock Ventures

Moderated by Keiran English, Partner, Spencer Stuart


October 2019: The Evolving Role of Artificial Intelligence & Blockchain Technology in Drug Discovery

Rosana Kapellar, EIR, Google Ventures

Arthur Hiller, Chief Corporate Development Office, Nuritas

Bennett Moore, Lead Digital Asset Resource, RSM US

Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities


September 2019: The Nuts & Bolts of Company Formation

Paulina Hill, Partner, Omega Funds

Samantha Truex, CEO, Quench Bio

Brian Goldstein, Partner, Choate Hall & Stewart

Scott Hansen, Managing Director, Pacific Western Bank

Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities


May 2019: Charles River Fever: Is a Cambridge Address Necessary for Success?

Robert Urban, Former/Retired Global Head, Johnson & Johnson Innovation, LLC

Jim Broderick, CEO, Palleon Pharmaceuticals

Paula Cloghessy, Chief Human Resources Officer, Translate Bio

Dave Melville, CEO & Founder, The Bowdoin Group

Moderated by Bruce Ledoux, Executive Director, JP Morgan Securities


March 2019: Measuring Readiness and Preparing your IPO

Reenie McCarthy, CEO, Stealth Biotherapeutics

John Maxwell, CFO, Aquestive Therapeutics

Gregg Beloff, Managing Director, Danforth Advisors

Moderated by Greg Schernecke, Partner at Dechert LLP


February 2019: Company Growth & Evolution of the Board

Praveen Tipirneni, CEO, Morphic Therapeutics

Bill Collins, Partner, Life Sciences Practice at Goodwin

Bruce Rycklik, Managing Partner at Park Square Executive Search

Moderated by Bruce Ledoux, JP Morgan Securities


December 2018: Policy, Pricing & Patient Affordability: A Discussion on Reimbursement

Amitabh Chandra, Harvard Business School and Harvard Kennedy School of Government

Jamey Millar, GlaxoSmithKline

Moderated by Bruce Ledoux, JP Morgan Securities


October 2018: Patent Strategy & Management: IP Diligence for Companies & Investors & Maximizing Portfolio ROI

John McDonald, Biogen

Paul Burgess, Translate Bio

Karen Sinclair, Harvard University

Moderated by Andrea Reid, Dechert LLP


September 2018: The Evolution of Finance

Steve Robinette, Atlas Ventures

David Ke, JP Morgan

Michal Preminger, J&J Innovation Center

Brian Goldstein, Choate, Hall & Stewart LLP

Moderated by Bruce Ledoux, JP Morgan Securities


May 2018: Structuring of Equity Compensation Models

Jeb Keiper, Nimbus Therapeutics

Paula Cloghessy, Translate Bio

Anne Longmire, JP Morgan Securities

Ram Kumar, Radford

Moderated by Bruce Ledoux, JP Morgan Securities


April 2018: Analysis of Oligonucleotides: Pros & Cons of Various Analytical Platforms

David Citerone, Frontage Laboratories

Jing Li, Alnylam Pharmaceuticals


February 2018: Tax Reform and its Implications to the Biotech Executive

Adam Frank, JP Morgan Securities

Robert McDonald, Partner, RSM

Moderated by Bruce Ledoux, JP Morgan Securities


November 2017: Strategic vs IPO: A Point & Counterpoint Discussion

Ron Renaud, CEO, Translate Bio

Doug Fambrough, CEO, Dicerna Pharmaceuticals

Moderated by Bruce Ledoux, JP Morgan Securities


October 2017: Advances in Biomolecule Analysis: A CMC Perspective

X. Sunney Xie- Harvard University

Desiree Tsao- Momenta Pharmaceuticals

Min Zhao- Frontage Labs


June 2017: Maximizing Value in a Merger & Acquisition or IPO Transaction

Phil Ross, JP Morgan


April 2017: Approaches to Immunogenicity Validations and the Impact of the Data on Early Clinical Development

Kevin Carleton- inVentiv Health

Susan Sloan- Visterra, Inc.


March 2017: Real World Evidence: The Convergence of Commercial & Clinical

David Thompson- inVentiv Health

Paul Hodgkins- Vertex

Arthur Hiller- Antyllus Therapeutics

Bryan Katz- inVentiv Health


December 2016: Holiday Cocktail Party


November 2016: Investigations into ISR (Incurred Sample Reproducibility) Failures

Pierre-Yves Caron- inVentiv Health

Case Studies presented by Krista Condon (Eisai), Eric David (Biogen), Estela Skende (Sunovion),

Heidi Mangus (Agios), and Mark Milton (Novartis)


September 2016: Regulatory Strategy

Carolyn Finkle- inVentiv Health

Stephane Lamouche- inVentiv Health


June 2016: Bioanalytical Challenges in Gene & Cellular Therapies and Biotherapeutics

Lilian Yengi- Bluebird Bio

Thomas Oglesby- inVentiv Health


May 2016: Commercial Viability

Angus Bromley- inVentiv Health

Waynne Waterfield- inVentiv Health

Arthur Hiller- Commercial Strategy Consultant


March 2016: Use of Proteomics to Identify Biomarkers

Richard Lipscombe- Proteomics International

Ru Wei- Biogen


Sept 2015: QT Assessments in Early Phase Trials

Borje Darpo- iCardiac Technologies, Inc

Sherilyn Adcock- Worldwide Clinical Trials


June 2015: CRO Selection: What are you looking for in your CRO Partner?

Liyu Yang- Biogen

Jim Vath- Zafgen

Peter Benton- Worldwide Clinical Trials


March 2015: Use of Adaptive Protocols in Drug Development

Jim Gilbert- True North Therapeutics

Gordon Loewen- Forum Pharmaceuticals

Darrell Nix- Drug Development Consulting


Sept 2014: When Novelty is not Enough: Creating Value Early and Throughout the Development Process

Mike Murphy- Worldwide Clinical Trials


May 2014: Use of Radiolabeled Studies in your Development Program

Wim Tamminga- QPS

Eric Solon- QPS


Jan 2014: The New Draft FDA BMV Guidance


September 2013: Validation of Biomarkers in the Bioanalytical Lab

Juan Chavez- Biogen

Jeff Moran- QPS


June 2013: Development of Bioanalytical Strategies for Characterization of Antibody Drug Conjugates (ADCs)

Dawn Dufield- Pfizer

Seema Kumar- Pfizer


March 2013: Issues with Metabolites

Caroline Lee- QPS


Jan 2013: Challenges in Alzheimer's Drug Development

Manfred Windisch- QPS (formerly JSW Life Sciences)


Oct 2012: Combining Autoradiography and Bioanalytical Techniques in Drug Discovery

Grace Poon- Syndexa

Eric Solon- QPS


June 2012: Preclinical Data Frontloading: An ADMET Perspective

Sanjeev Thohan, Novartis

Jian Yu- QPS


Jan 2012: New EMA BMV Guidance

Jeff Moran- QPS


Oct 2011: Protein analysis by LC-MS/MS

Joe Palandra- Pfizer

Ben van Baar- QPS


June 2011: Tissue Bioanalysis

Stacy Ho - Genzyme

Zamas Lam - QPS


March 2011: Dry Blood Spot

Krista Condon - Eisai

Jaap Weiling - QPS